title: Thromboprophylaxis for women undergoing caesarean section.
abstract: Thromboprophylaxis for women undergoing caesarean section (CS) was introduced in the hospital in 1995. This study audited the use of tinzaparin prophylaxis in a nested cohort of women who screened negative for diabetes mellitus at 28 weeks gestation. All the women had their weight measured and BMI calculated at the first antenatal visit. Of the 284 women, 68 (24%) had a CS and all received tinzaparin. Of the 68, however, 94% received a dose lower than recommended. Compliance with prophylaxis was complete but compliance with the recommended dosage was suboptimal, which may result in venous thromboembolism after CS despite thromboprophylaxis.
authors.affiliation: UCD Centre for Human Reproduction, Coombe Women and Infant's University Hospital, Cork St, Dublin 8.
authors.forename: C
authors.initials: C
authors.lastname: Kennedy
authors.forename: V
authors.initials: V
authors.lastname: O'Dwyer
authors.forename: S
authors.initials: S
authors.lastname: O'Kelly
authors.forename: N
authors.initials: N
authors.lastname: Farah
authors.forename: M
authors.initials: M
authors.lastname: Kennelly
authors.forename: M J
authors.initials: MJ
authors.lastname: Turner
mesh_terms: D002585:Cesarean Section; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D019983:Guideline Adherence; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage; D006801:Humans; D011446:Prospective Studies; D000078222:Tinzaparin; D020246:Venous Thrombosis / Q000517:prevention & control*
chemical_list: D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D000078222:Tinzaparin